12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

Inclusion Criteria: * Diagnosis of clinically isolated syndrome or a relapsing form(s) of MS, based on Poser or McDonald criteria (may include patients with secondary progressive disease) * Clinical relapse within the past 3 years or a gadolinium enhancing lesion on a brain MRI scan within the past 12 months * Baseline EDSS score of 0 - 6.5 * Female subjects who are sexually active, unless sterile or post-menopausal for at least 1 year, must be willing to use double-barrier contraception Exclusion Criteria: * Primary progressive MS * Any medical condition that predisposes to immunocompromise * History of malignancy, tuberculosis, invasive fungal infections, herpes zoster infection (or shingles), or other opportunistic infection, or any current active infection * Concurrent diagnosis of any other autoimmune disease (eg, rheumatoid arthritis or lupus) * Treatment with cyclophosphamide or mitoxantrone within 6 months of study initiation * Treatment with cyclosporine, azathioprine, methotrexate or other immunosuppressant within 3 months of study initiation * Treatment with interferon beta or glatiramer acetate within 2 months of study initiation * Prior treatment with natalizumab or rituximab